Clariscan

Indications

• Magnetic resonance imaging in various anatomical regions
• Evaluation of vascular diseases
• Assessment of tumors and other lesions

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing information, as it may vary based on age and weight.

Adults: The recommended dose for adults is typically 0.1 mmol/kg body weight, administered as a slow intravenous injection. The exact dosage may vary based on the specific imaging requirements and protocols.

Mechanism of action

Gadoterate works by providing contrast during MRI procedures through its paramagnetic properties. When injected into the bloodstream, gadoterate influences the magnetic resonance signals of surrounding water protons. The presence of gadolinium ions enhances signal intensity, allowing for clearer imaging of vascular structures and pathological lesions.

Pharmacodynamics

Gadoterate exhibits a strong magnetic susceptibility due to the gadolinium ion, which assists in altering the relaxation times of nearby protons in tissues. This leads to improved contrast differentiation between normal and abnormal tissues in MRI. The degree of enhancement depends on the concentration of the contrast agent and the specific MRI sequences used.

Pharmacokinetics

After intravenous administration, gadoterate is rapidly distributed in the vascular system, with the peak concentration occurring within minutes. It has a volume of distribution that reflects the extracellular fluid space. The elimination half-life is typically around 1.5 to 2 hours, with the majority of the drug excreted unchanged in urine within 24 hours. Gadoterate does not undergo significant metabolism.

Pregnancy

There is limited data on the use of gadoterate in pregnancy. It should only be used if the benefits outweigh the risks.

Breast-feeding

It is not known whether gadoterate is excreted in human milk. Caution is advised when administering to breastfeeding mothers.

Storage

Store at 15 to 25 degrees Celsius. Protect from light and freeze.

Formulations

• Injection

Indications

• Magnetic resonance imaging of the brain and spinal cord
• Magnetic resonance angiography
• Assessment of tumors and lesions in various tissues
• Evaluation of vascular malformations
• Imaging of the abdomen and pelvis

Dosage

Children: Refer to the specific guidelines provided in the BNF for Children for paediatric dosing.

Adults: Refer to the specific guidelines provided in the BNF or local protocols for adult dosing.

Mechanism of action

Gadoteric works by altering the magnetic properties of nearby water protons in the body tissues. The presence of gadolinium ions in the contrast agent shortens the T1 relaxation time of these protons, resulting in increased signal intensity on T1-weighted MRI images. This enhancement provides better contrast between different tissues, helping to highlight abnormalities such as tumors, inflammation, or vascular changes.

Pharmacodynamics

The pharmacodynamics of gadoteric is characterized by its ability to affect the magnetic resonance signal, thus enhancing the visibility of certain tissues during imaging. The efficacy of gadoteric is influenced by its distribution in the body, which is primarily vascular and interstitial. Its contrast effect is contingent upon the concentration of the gadolinium ions at the site of interest and the timing of imaging after administration.

Pharmacokinetics

Gadoteric is administered intravenously and is rapidly distributed throughout the vascular compartment. It has a low protein binding capacity and is primarily excreted unchanged via the kidneys. The elimination half-life of gadoteric is approximately 1.5 to 2 hours in patients with normal renal function. In cases of renal impairment, the elimination may be prolonged, necessitating careful consideration of the patient's renal status before administration.

Contra-indications

• Hypersensitivity to gadoteric acid or any of the excipients
• Severe renal impairment (eGFR <30 mL/min)

Adverse effects

• Nausea
• Headache
• Dizziness
• Injection site reactions
• Hypersensitivity reactions
• Nephrogenic systemic fibrosis (in patients with severe renal impairment)

Interactions

• Other gadolinium-based contrast agents
• Certain medications that affect renal function may increase the risk of nephrogenic systemic fibrosis

Precautions

• Use with caution in patients with renal impairment
• Assess renal function before administration
• Monitor for signs of hypersensitivity during and after administration

Pregnancy

Safety in pregnancy has not been established. Use only if necessary and if the potential benefits justify the risks to the fetus.

Breast-feeding

It is not known whether gadoteric is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store at 20-25 degrees Celsius. Protect from light. Do not freeze.

Formulations

• Gadoteric acid injection solution

Indications

• Pain management
• Vaccination
• Antibiotic therapy
• Hormonal therapies
• Anesthesia
• Nutritional support
• Chemotherapy

Dosage

Children: Refer to specific drug guidelines for paediatric dosing, as it requires careful consideration of weight and age.

Adults: Refer to specific drug guidelines for adult dosing, as it varies widely depending on the medication and clinical condition.

Mechanism of action

The mechanism of action of injected drugs varies widely based on the specific medication being administered. Generally, injected drugs enter the bloodstream directly, allowing them to circulate rapidly throughout the body. For instance, antibiotics may work by inhibiting bacterial cell wall synthesis, while analgesics may modulate pain pathways in the central nervous system. Each drug has unique pathways through which it achieves its therapeutic effects.

Pharmacodynamics

Pharmacodynamics refers to the effects of drugs on the body and their mechanisms of action. For injectable medications, effects can be immediate or delayed, depending on the drug's formulation and route of administration. Factors influencing pharmacodynamics include receptor affinity, drug concentration, and the presence of other substances that may enhance or inhibit the drug's effects. For example, some injectable drugs may require specific receptors to exert their effects, while others may have a broader range of action.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of injected drugs. After administration, drugs are rapidly absorbed into the bloodstream, leading to quick therapeutic effects. The distribution depends on factors such as blood flow, tissue permeability, and protein binding. Drugs are metabolized primarily in the liver and excreted through the kidneys or bile. The pharmacokinetic profile can vary widely based on the drug's chemical nature, dosage, and individual patient factors.

Pregnancy

Safety during pregnancy depends on the specific injection and its active ingredients. It is essential to consult a healthcare professional for guidance.

Breast-feeding

The safety of injections during breastfeeding varies by the specific medication. It is recommended to seek advice from a healthcare provider.

Storage

Store injections as per manufacturer's guidelines, usually in a cool, dry place away from direct sunlight. Some may require refrigeration.

Indications

• Used as a solubilizing agent in pharmaceutical preparations
• Used in radiographic contrast media formulations

Dosage

Children: Refer to specific formulations for paediatric dosing instructions as it varies depending on the application.

Adults: Refer to specific formulations for adult dosing instructions as it varies depending on the application.

Mechanism of action

Meglumine acts by enhancing the solubility and stability of drugs in solution, particularly in radiographic contrast agents. It is involved in purinergic signaling pathways, which are essential for various physiological processes, including neurotransmission and inflammation.

Pharmacodynamics

The pharmacodynamic profile of meglumine is largely influenced by its role as a solubilizing agent. It does not exhibit direct pharmacological effects on its own but rather facilitates the action of other active ingredients in formulations. Its impact on purinergic signaling may contribute to modulating physiological responses in the body.

Pharmacokinetics

Meglumine is rapidly absorbed when administered, with its pharmacokinetics closely tied to the properties of the drugs it accompanies. The distribution, metabolism, and excretion of meglumine are not well-defined as it typically functions as an excipient rather than an active therapeutic agent. Its elimination from the body is primarily via renal pathways.

Pregnancy

There is insufficient data on the use of meglumine in pregnancy, therefore it should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering meglumine to breastfeeding women, as its effects on infants are not well studied.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.